Article
Oncology
Issa F. Khouri, Denai R. Milton, Alison M. Gulbis, Elias J. Jabbour, Loretta Nastoupil, Celina Ledesma, Paolo Anderlini, Qaiser Bashir, May Daher, Jin S. Im, Swaminathan P. Iyer, David Marin, Rohtesh S. Mehta, Amanda L. Olson, Uday R. Popat, Muzaffar Qazilbash, Neeraj Saini, Felipe Samaniego, Gabriela Rondon, L. Jeffrey Medeiros, Richard E. Champlin
Summary: In patients with relapsed follicular lymphoma, receiving alloSCT has been shown to confer better overall survival and progression-free survival compared to autoSCT.
CLINICAL CANCER RESEARCH
(2021)
Article
Biophysics
M. L. Dworkin, A. L. Jiang, R. Von Eyben, M. A. Spinner, R. H. Advani, R. Lowsky, S. M. Hiniker, R. T. Hoppe
Summary: The study evaluated the impact of antithymocyte globulin conditioning with radiation boost on survival before allogeneic hematopoietic cell transplant for adults with lymphoma. The results suggested that radiation boost may help mitigate the risk of high-risk or residual disease in this population undergoing allo-HCT.
BONE MARROW TRANSPLANTATION
(2022)
Article
Oncology
Reid W. Merryman, Luca Castagna, Laura Giordano, Vincent T. Ho, Paolo Corradini, Anna Guidetti, Beatrice Casadei, David A. Bond, Samantha Jaglowski, Michael A. Spinner, Sally Arai, Robert Lowsky, Gunjan L. Shah, Miguel-Angel Perales, Jean Marc Schiano De Colella, Didier Blaise, Alex F. Herrera, Geoffrey Shouse, Chloe Spilleboudt, Stephen M. Ansell, Yago Nieto, Talha Badar, Mehdi Hamadani, Tatyana A. Feldman, Lori Dahncke, Anurag K. Singh, Joseph P. McGuirk, Taiga Nishihori, Julio Chavez, Anthony V. Serritella, Justin Kline, Mohamad Mohty, Remy Dulery, Aspasia Stamatoulas, Roch Houot, Guillaume Manson, Marie-Pierre Moles-Moreau, Corentin Orvain, Kamal Bouabdallah, Dipenkumar Modi, Radhakrishnan Ramchandren, Lazaros Lekakis, Amer Beitinjaneh, Matthew J. Frigault, Yi-Bin Chen, Ryan C. Lynch, Stephen D. Smith, Uttam Rao, Michael Byrne, Jason T. Romancik, Jonathon B. Cohen, Sunita Nathan, Tycel Phillips, Robin M. Joyce, Maryam Rahimian, Asad Bashey, Hatcher J. Ballard, Jakub Svoboda, Valter Torri, Martina Sollini, Chiara De Philippis, Massimo Magagnoli, Armando Santoro, Philippe Armand, Pier Luigi Zinzani, Carmelo Carlo-Stella
Summary: Anti-PD-1 monoclonal antibodies have shown high response rates in classic Hodgkin lymphoma patients, but relapse is common. Allogeneic hematopoietic cell transplantation (alloHCT) after PD-1 blockade carries increased toxicity, with post-transplant cyclophosphamide (PTCy) prophylaxis showing significant improvements in progression-free survival (PFS) and graft-versus-host disease (GVHD)-free survival (GRFS).
Article
Biophysics
Walter J. F. M. van der Velden, Goda Choi, Moniek A. de Witte, Arnold van der Meer, Anton F. J. de Haan, Nicole M. A. Blijlevens, Gerwin Huls, Jurgen Kuball, Suzanne van Dorp
Summary: The use of ATG in HLA-mismatched nonmyeloablative HCT is feasible and results in acceptable long term outcomes, especially in terms of GRFS. ATG in combination with cyclosporin and mycophenolate mofetil could be considered as an alternative to the triple drug strategy using sirolimus for GVHD prophylaxis in this specific setting.
BONE MARROW TRANSPLANTATION
(2021)
Article
Hematology
Cole H. Sterling, Hua-Ling Tsai, Matthias Holdhoff, Javier Bolanos-Meade, Leo Luznik, Ephraim J. Fuchs, Carol Ann Huff, Christian B. Gocke, Syed Abbas Ali, Ivan M. Borrello, Ravi Varadhan, Richard J. Jones, Douglas E. Gladstone, Richard F. Ambinder, Nina Wagner-Johnston, Lode J. Swinnen, Philip H. Imus
Summary: AlloBMT treatment for secondary CNS lymphoma shows promising results, with a median overall survival not reached, a median progressionfree survival of 3.8 years, a relapse rate of 25%, and a nonrelapse mortality rate of 30%. The use of alloBMT in CNS lymphoma warrants further investigation.
TRANSPLANTATION AND CELLULAR THERAPY
(2021)
Article
Hematology
Nobuaki Nakano, Atae Utsunomiya, Keitaro Matsuo, Noriaki Yoshida, Masao Seto, Kouichi Ohshima, Hiroshi Fujiwara, Shigeo Fuji, Yoshifusa Takatsuka, Ayumu Ito, Toshihiro Miyamoto, Youko Suehiro, Hirohisa Nakamae, Yasushi Sawayama, Mitsuhiro Yuasa, Yasuhiko Miyazaki, Shuichi Ota, Kazunori Imada, Takahiro Fukuda, Tatsuo Ichinohe, Yoshiko Atsuta, Koji Kato
Summary: This study investigated the impact of chromosomal abnormalities on the survival of ATL patients after allo-HSCT, and found that certain structural breakpoints were independent risk factors for overall survival and ATL-related death.
Article
Hematology
Fateeha Furqan, Kwang W. Ahn, Yue Chen, Manmeet Kaur, Syed A. Abutalib, Nausheen Ahmed, Sairah Ahmed, Mohamed A. Kharfan-Dabaja, Johnathan Friedberg, Tara Gregory, LaQuisa Hill, Cole Sterling, Stephan K. Barta, Mazyar Shadman, Miguel-Angel Perales, Jasmine Zain, Alex F. Herrera, Craig Sauter, Mehdi Hamadani
Summary: This study evaluated the outcomes of allo-HCT in patients with relapsed/refractory ALCL and found that it can result in durable disease control in a significant proportion of patients. However, refractory disease and racial minority status predicted inferior outcomes after allo-HCT.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Chun-Hui Lee, Tzu-Chien Lin, Ming Yao, Liang-Tsai Hsiao, Bor-Sheng Ko, Chia-Jen Liu, Tsai-Yun Chen
Summary: This study analyzed the long-term follow-up data of patients who underwent allo-HSCT in Taiwan and found that allo-HSCT could be a salvage therapeutic option for relapsed or refractory B-cell lymphoma. Complete remission at the time of allo-HSCT and the presence of GVHD were independent variables for overall survival.
Article
Medicine, General & Internal
Chunmeng Rong, Lixia Sheng, An Wu, Ye Sun, Guifang Ouyang
Summary: There is currently no established standard guideline for the treatment of plasmablastic lymphoma (PBL), which has a poor prognosis due to early relapse after chemotherapy. This case study presented a 52-year-old HIV-negative man with PBL who achieved complete remission after induction therapy but relapsed after autologous hematopoietic stem cell transplantation. Following salvage allogeneic hematopoietic stem cell transplantation, the patient achieved remission again and has been disease-free for over 4 years. Further clinical studies are needed to explore the role of allogeneic hematopoietic stem cell transplantation in refractory and recurrent PBL.
Article
Oncology
Nina Orfali, Yuliya Jhanwar, Calvin Koo, Michelle Pasciolla, Maria Baldo, Edwidge Cuvilly, Richard Furman, Usama Gergis, June Greenberg, Danielle Guarneri, Jing-Mei Hsu, John P. Leonard, Tomer Mark, Sebastian Mayer, Kathleen Maignan, Peter Martin, Adomah Opong, Roger Pearse, Adrienne Phillips, Adriana Rossi, Jia Ruan, Sarah C. Rutherford, Jessy Ryan, Grace Suhu, Koen Van Besien, Tsiporah Shore
Summary: The study evaluated the safety and efficacy of using bendamustine as a bridge to stem cell transplantation in patients with relapsed/refractory lymphoma, with findings indicating potential benefits for some patients while also raising the risk of therapy-related myeloid neoplasia. Bendamustine did not cause toxicities precluding transplantation, but there were cases of therapy-related myeloid neoplasia observed in some patients, suggesting a need for careful consideration of risks and benefits in clinical decision-making.
LEUKEMIA & LYMPHOMA
(2021)
Article
Oncology
Bita Fakhri, Elif Yilmaz, Feng Gao, Richard F. Ambinder, Richard Jones, Nancy L. Bartlett, Amanda Cashen, Nina Wagner-Johnston
Summary: For relapsed Hodgkin lymphoma, salvage chemotherapy followed by auto-HCT is the standard of care. It is important to identify subpopulations who could benefit from allo-HCT. The choice of transplant (auto-HCT or allo-HCT) did not affect PFS or OS after controlling for risk factors, but in patients with >= 3 high risk features, those who underwent allo-HCT had a slightly better 4-year PFS compared to the auto-HCT cohort.
LEUKEMIA & LYMPHOMA
(2021)
Article
Oncology
A. Kopinska, A. Koclega, A. Wieczorkiewicz-Kabut, K. Wozniczka, D. Kata, M. Wlodarczyk, G. Helbig
Summary: Refractory and relapsed Hodgkin lymphoma patients who underwent allogeneic stem cell transplantation showed a 2-year overall survival of 40%. Chemosensitive disease at transplant entry was associated with better outcomes, despite some patients developing graft-versus-host disease. Allo-SCT remains a potential curative approach for long-term survival in this high-risk patient population.
PATHOLOGY & ONCOLOGY RESEARCH
(2021)
Article
Hematology
G. Gutierrez-Garcia, C. Martinez, A. Boumendil, H. Finel, R. Malladi, B. Afanasyev, A. Tsoulkani, K. M. O. Wilson, A. Bloor, M. Nikoloudis, D. Richardson, L. Lopez-Corral, L. Castagna, J. Cornelissen, A. Giltat, M. Collin, R. Fanin, F. Bonifazi, S. Robinson, S. Montoto, K. S. Peggs, A. Sureda
Summary: The study found that in high-risk HL patients, a MAC strategy with TCD may be the best option, showing better survival outcomes compared to reduced-intensity conditioning regimens with TCD.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Editorial Material
Medicine, General & Internal
Dan L. Longo, James O. Armitage
Summary: Treatment for Hodgkin's lymphoma has been a success in modern medicine. The once fatal disorder is now curable in the majority of patients, even in advanced stages. The focus of treatment is on maintaining high cure rates while reducing toxic effects. The best approach for advanced-stage, high-risk patients is currently debated.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Review
Oncology
Miriam Marangon, Carlo Visco, Anna Maria Barbui, Annalisa Chiappella, Alberto Fabbri, Simone Ferrero, Sara Galimberti, Stefano Luminari, Gerardo Musuraca, Alessandro Re, Vittorio Ruggero Zilioli, Marco Ladetto
Summary: Mantle Cell Lymphoma (MCL) is a rare lymphoproliferative disorder that has been regarded as incurable since its identification. For two decades, allogeneic transplantation has been the only option capable of ensuring prolonged remissions and potential cure. However, its application has been limited by feasibility constraints and significant toxicity, particularly in elderly patients.
Article
Hematology
Anna Hecht, Julia A. Meyer, Astrid Behnert, Eric Wong, Farid Chehab, Adam Olshen, Aaron Hechmer, Catherine Aftandilian, Rukhmi Bhat, Sung Won Choi, Satheesh Chonat, Jason E. Farrar, Mark Fluchel, Haydar Frangoul, Jennifer H. Han, Edward A. Kolb, Dennis J. Kuo, Margaret L. MacMillan, Luke Maese, Kelly W. Maloney, Aru Narendran, Benjamin Oshrine, Kirk R. Schultz, Maria L. Sulis, David Van Mater, Sarah K. Tasian, Wolf-Karsten Hofmann, Mignon L. Loh, Elliot Stieglitz
Summary: Mutations in the CBL gene can lead to various myeloid malignancies, with some pediatric patients with JMML carrying CBL mutations but having milder disease courses. The majority of CBL mutations in JMML patients are germline, not somatic mutations. The disease presentation and overall outcome of JMML patients with CBL mutations are highly diverse, and some patients have more aggressive disease with somatically acquired CBL mutations. Clinical features and methylation profiling cannot accurately distinguish patients with different types of CBL mutations, highlighting the need for germline testing.
Article
Hematology
Asim Saha, Sharon Hyzy, Tahirih Lamothe, Katelyn Hammond, Nicholas Clark, Leanne Lanieri, Prashant Bhattarai, Rahul Palchaudhuri, Geoffrey O. Gillard, Jennifer Proctor, Megan J. Riddle, Angela Panoskaltsis-Mortari, Margaret L. MacMillan, John E. Wagner, Hans-Peter Kiem, Lisa M. Olson, Bruce R. Blazar
Summary: Allo-HSCT is a potential curative treatment for blood disorders, but graft-versus-host disease (GVHD) limits its success. CD45-ADC, an antibody-drug-conjugate, facilitates stable donor cell engraftment and provides a new approach to reduce treatment toxicity.
Letter
Biophysics
Gabrielle Meyers, Mehdi Hamadani, Michael Martens, Haris Ali, Hannah Choe, Peter Dawson, Andrew C. Harris, Eric van Hooren, Willem Klaassen, Eric Leifer, Margaret L. MacMillan, Ypke van Oosterhout, Lia Perez, Iskra Pusic, Phuong Vo, John E. Levine
BONE MARROW TRANSPLANTATION
(2022)
Review
Hematology
Tewodros Mamo, Keli L. Hippen, Margaret L. MacMillan, Claudio G. Brunstein, Jeffrey S. Miller, John E. Wagner, Bruce R. Blazar, David H. McKenna
Article
Oncology
Martin Felices, Erin Wesley, Laura E. Bendzick, Behiye Kodal, Rachel Hopps, Bartosz Grzywacz, Peter Hinderlie, Jeffrey S. Miller, Melissa A. Geller
Summary: We investigated the effects of combined treatment with an IL15 superagonist (N-803) and immune checkpoint blockade (ICB) on immune activation in ovarian cancer patients. Our results showed that N-803 stimulated initial expansion of natural killer (NK) cells in patients, and combining ICB enhanced NK cell function. In preclinical studies, the combination of N-803 and ICB also showed improved anti-tumor control and enhanced NK cell persistence and expansion in vivo.
CANCER IMMUNOLOGY RESEARCH
(2023)
Review
Oncology
Jawad Fares, Zachary B. Davis, Julian S. Rechberger, Stephanie A. Toll, Jonathan D. Schwartz, David J. Daniels, Jeffrey S. Miller, Soumen Khatua
Summary: Despite current treatment advancements for brain tumors, including surgery, chemotherapy, and radiation, the prognosis remains poor, especially for recurrent cases. The close proximity to delicate neural structures often prevents complete surgical removal, and the toxicities of systemic therapy are a concern. However, the field of NK cell-based cancer therapy shows promise as a new avenue for treating brain tumors.
NPJ PRECISION ONCOLOGY
(2023)
Letter
Biophysics
Gabrielle Meyers, Mehdi Hamadani, Michael Martens, Haris Ali, Patrice Chevallier, Hannah Choe, Andrew C. Harris, Ernst Holler, Eric van Hooren, Willem Klaassen, Eric Leifer, Ypke van Oosterhout, Lia Perez, Iskra Pusic, Matthias Stelljes, Walter van der Velden, Emanuele Ammatuna, David Beauvais, Jerome Cornillon, Richard T. Maziarz, Johannes Schetelig, Jennifer Romeril, Margaret L. MacMillan, John E. Levine, Gerard Socie
BONE MARROW TRANSPLANTATION
(2023)
Article
Hematology
Shernan G. Holtan, Andrea Hoeschen, Qing Cao, Celalettin Ustun, Brian C. Betts, Najla El Jurdi, Joseph Maakaron, Armin Rashidi, Jeffrey S. Miller, John E. Wagner, Bruce R. Blazar, Pamala A. Jacobson, Angela Panoskaltsis-Mortari, Daniel J. Weisdorf, Margaret L. Macmillan
Summary: Studies have shown that treatments that aid inflammation resolution, immune tolerance, and epithelial repair may improve outcomes for life-threatening acute graft-versus-host disease (aGVHD) beyond traditional immunosuppressants. Addition of urinary-derived human chorionic gonadotropin/epidermal growth factor (uhCG/EGF) to standard aGVHD therapy has been found to be a feasible supportive care measure with potential to reduce morbidity and mortality. Further research is needed to explore the efficacy of uhCG/EGF as a complementary treatment for aGVHD.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Article
Hematology
Nancy Gillis, Eric Padron, Tao Wang, Karen Chen, Jakob D. Devos, Stephen R. Spellman, Stephanie J. Lee, Carrie L. Kitko, Margaret L. Macmillan, Jeffrey West, Yi -Han Tang, Mingxiang Teng, Samantha Mcnulty, Todd E. Druley, Joseph A. Pidala, Aleksandr Lazaryan
Summary: Improved treatment options enable older patients to receive potentially curative allogeneic hematopoietic cell transplantation. An unintended risk associated with older donors is the transplantation of donor cells with clonal hematopoiesis, which may affect transplantation outcomes.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Article
Hematology
Rima M. Salibaaw, Amin M. Alousia, Joseph Pidala, Mukta Arora, Stephen R. Spellman, Michael T. Hemmer, Tao Wang, Camille Abboudg, Sairah Ahmed, Joseph H. Antin, Amer Beitinjanehi, David K. Buchbinder, Michael Byrne, Jean-Yves Cahn, Hannah Choen, Rabi Hanna, Peiman HemattiP, Rammurti T. Kamble, Carrie L. Kitkor, Mary Laughlin, Lazaros Lekakis, Margaret L. MacMillan, Rodrigo Martino, Parinda A. Mehta, Taiga Nishihori, Sagar S. Patel, Miguel-Angel Perales, Hemalatha G. Rangarajan, Olov Ringden, Joseph Rosenthal, Bipin N. Savani, Kirk R. Schultz, Sachiko Seo, Takanori Teshimaag, Marjolein van der Poela, Leo F. Verdonck, Daniel Weisdorf, Baldeep Wirk, Jean A. Yared, Jeffrey Schriber, Richard E. Champlin, Stefan O. Ciurea
Summary: This retrospective registry study compared the distribution, severity, and outcomes of graft-versus-host disease (GvHD) in patients receiving haploidentical (Haplo) transplantation with post-transplantation cyclophosphamide (PTCy) prophylaxis and HLA-matched unrelated donor transplantation with conventional prophylaxis. The study found that Haplo/PTCy transplantation was associated with reduced rates of severe acute GvHD and chronic GvHD, particularly in the gastrointestinal (GI) tract.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)
Article
Hematology
Catherine J. Lee, Tao Wang, Karen Chen, Mukta Arora, Ruta Brazauskas, Stephen R. Spellman, Carrie Kitko, Margaret L. MacMillan, Joseph A. Pidala, Jeffery J. Auletta, Sherif M. Badawy, Neel Bhatt, Vijaya R. Bhatt, Jean-Yves Cahn, Zachariah DeFilipp, Miguel A. Diaz, Nosha Farhadfar, Shahinaz Gadalla, Robert P. Gale, Hasan Hashem, Shahrukh Hashmi, Peiman Hematti, Sanghee Hong, Nasheed M. Hossain, Yoshihiro Inamoto, Lazaros J. Lekakis, Dipenkumar Modi, Sager Patel, Akshay Sharma, Scott Solomon, Daniel R. Couriel
Summary: Chronic graft-versus-host disease (cGVHD) is a common complication following allogeneic hematopoietic cell transplantation (HCT) in children, and it significantly affects the quality of life of long-term survivors. This study aimed to analyze the occurrence of late effects (LEs) in pediatric HCT survivors and investigate the correlation between cGVHD and subsequent neoplasms (SNs) and nonmalignant LEs (NM-LEs). The findings suggest that patients with cGVHD have a higher cumulative incidence of LEs within 10 years after HCT, and cGVHD-related features are closely associated with the occurrence of NM-LEs.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)
Article
Hematology
Jo-Anne H. Young, Najla El Jurdi, Ahmad Rayes, Margaret L. MacMillan, Shernan G. Holtan, Qing Cao, Judith Witte, Mukta Arora, Daniel J. Weisdorf
Summary: This study retrospectively analyzed the infectious complications in patients with acute graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT). The results showed that patients with steroid-sensitive GVHD had fewer bacterial and viral infections compared to patients with steroid-resistant GVHD. The study suggests that anti-infective therapy should be guided by infection density during active GVHD treatment.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)
Article
Biochemistry & Molecular Biology
Christopher J. Sipe, Mitchell G. Kluesner, Samuel P. Bingea, Walker S. Lahr, Aneesha A. Andrew, Minjing Wang, Anthony P. DeFeo, Timothy L. Hinkel, Kanut Laoharawee, John E. Wagner, Margaret L. MacMillan, Gregory M. Vercellotti, Jakub Tolar, Mark J. Osborn, R. Scott McIvor, Beau R. Webber, Branden S. Moriarity
Summary: Fanconi anemia is a rare genetic disease characterized by a lack of genes essential for DNA repair. Researchers have used digital genome editing to correct the mutated genes in patient cells, resulting in phenotypic rescue.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Hematology
Abdelrahman Saqr, Brooke Carlson, Christopher Staley, Armin Rashidi, Mahmoud Al-Kofahi, Thomas Kaiser, Shernan Holtan, Margaret MacMillan, Jo-Anne Young, Najla El Jurdi, Daniel Weisdorf, Alexander Khoruts, Pamala A. Jacobson
Summary: Mycophenolate mofetil (MMF) is an important immunosuppressant used after allogeneic hematopoietic cell transplantation (HCT). This study found that blood concentrations of MMF were highly variable, with low concentrations associated with the risk of graft-versus-host disease (GVHD) and high concentrations associated with toxicity. The presence of beta-glucuronidase-producing bacteria in the gastrointestinal tract may enhance the enterohepatic recirculation (EHR) of MMF, leading to higher concentrations. Individuals with high EHR had a greater abundance of certain Bacteroides species in their stool and higher exposure to MMF.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)
Article
Hematology
Vijaya Raj Bhatt, Tao Wang, Karen Chen, Carrie L. Kitko, Margaret L. MacMillan, Joseph A. Pidala, Monzr M. Al Malki, Sherif M. Badawy, Amer Beitinjaneh, Siddhartha Ganguly, Betty Hamilton, Gerhard C. Hildebrandt, Lazaros J. Lekakis, Hongtao Liu, Richard T. Maziarz, Dipenkumar Modi, Hemant S. Murthy, Jaime M. Preussler, Akshay Sharma, Stephen R. Spellman, Mukta Arora, Stephanie J. Lee
Summary: In this study, the effect of chronic graft-versus-host disease (cGVHD) on nonrelapse mortality (NRM) and relapse risk was investigated in older adults undergoing allogeneic hematopoietic cell transplantation. The results revealed that cGVHD significantly increased the risk of NRM and decreased the risk of relapse, regardless of age. Older adults had a higher risk of NRM, but the impact of cGVHD on NRM did not differ based on age.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)
